Integra LifeSciences Holdings Corporation (IART)
Integra LifeSciences lowers revenue and earnings outlook for 2026
Integra Lifesciences Holdings Corp (NASDAQ:IART) cut its 2026 revenue and adjusted earnings guidance after July flooding disrupted operations in Cincinnati, despite expectations for strong cash generation. The medical technology company now forecasts annual revenue of $1.634 billion to $1.654 billion, down from $1.654 billion to $1.695 billion.
IART vs. PEN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
Here's Why Integra LifeSciences (IART) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Integra LifeSciences Holdings Corporation (IART) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Integra LifeSciences Holdings Corporation (IART) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Integra LifeSciences: Strong Q2 2026 Results Support Recovery Thesis
Integra LifeSciences Holdings is a turnaround story, maintaining a BUY rating after a strong 2Q26 earnings beat and margin expansion. IART's specialty surgery segment led revenue, while tissue reconstruction saw declines offset by a successful PriMatrix relaunch and upcoming SurgiMend reintroduction. Management targets leverage reduction to 2.5–3.5x by end-2026, prioritizing debt repayment as operating cash flow improves.
Integra (IART) Down 1.6% Since Last Earnings Report: Can It Rebound?
Integra (IART) reported earnings 30 days ago. What's next for the stock?
Why Integra LifeSciences (IART) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?
Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.
Is IART Still Attractive as Its Low Valuation Meets Execution Risks?
Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.
Here's Why Integra LifeSciences (IART) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Integra (IART) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Integra LifeSciences Q2 Earnings Call Highlights
Integra LifeSciences NASDAQ: IART reported second-quarter 2026 revenue of $419 million, up 0.8% on a reported basis and 0.7% organically from a year earlier, as improving supply reliability and operational execution supported results. Adjusted earnings per share rose 24% year over year to $0.56, exceeding the company's guidance range.
